Summary of Study ST002864

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001786. The data can be accessed directly via it's Project DOI: 10.21228/M8VB1G This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002864
Study TitleMetabolic profiling, glucose tracing and glutamine tracing in naive and Enzalutamide-treated 16D prostate cancer cells expressing RFP or MYC
Study SummaryAdvanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploit therapy-induced phenotypes prior to the outgrowth of treatment-resistant disease. Here, we comprehensively characterize the effect of AR blockade on prostate cancer metabolism using transcriptomics, metabolomics and bioenergetics approaches. The metabolic response to AR inhibition is defined by reduced glycolysis, robust elongation of mitochondria, and increased reliance on mitochondrial oxidative metabolism. We establish DRP1 activity and MYC signaling as mediators of AR blockade-induced metabolic phenotypes. Rescuing DRP1 phosphorylation after AR inhibition restores mitochondrial fission, while rescuing MYC restores glycolytic activity and prevents sensitivity to complex I inhibition. Our study provides new insight into the regulation of treatment-induced metabolic phenotypes and vulnerabilities in prostate cancer. In the MS data, M0, M1, M2, M3,... represent isotopologues of each metabolite.
Institute
University of California, Los Angeles
DepartmentMolecular, Cell and Developmental Biology
LaboratoryAndrew Goldstein
Last NameGoldstein
First NameAndrew
Address610 Charles E Young Dr East, Goldstein Lab 3141 Terasaki Life Sci Bld, Los Angeles, CA, 90095, USA
EmailAGoldstein@mednet.ucla.edu
Phone3102061402
Submit Date2023-09-12
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2023-09-19
Release Version1
Andrew Goldstein Andrew Goldstein
https://dx.doi.org/10.21228/M8VB1G
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA309450NN-010MYC_Enza_C13Glc
SA309451NN-011MYC_Enza_C13Glc
SA309452NN-012MYC_Enza_C13Glc
SA309453NN-022MYC_Enza_C13Gln
SA309454NN-024MYC_Enza_C13Gln
SA309455NN-023MYC_Enza_C13Gln
SA309456NN-005MYC_vehicle_C13Glc
SA309457NN-004MYC_vehicle_C13Glc
SA309458NN-006MYC_vehicle_C13Glc
SA309459NN-018MYC_vehicle_C13Gln
SA309460NN-016MYC_vehicle_C13Gln
SA309461NN-017MYC_vehicle_C13Gln
SA309462QC-blank1NA
SA309463QC-blank2NA
SA309464QC-blank3NA
SA309465NN-009RFP_Enza_C13Glc
SA309466NN-008RFP_Enza_C13Glc
SA309467NN-007RFP_Enza_C13Glc
SA309468NN-021RFP_Enza_C13Gln
SA309469NN-020RFP_Enza_C13Gln
SA309470NN-019RFP_Enza_C13Gln
SA309471NN-003RFP_vehicle_C13Glc
SA309472NN-002RFP_vehicle_C13Glc
SA309473NN-001RFP_vehicle_C13Glc
SA309474NN-014RFP_vehicle_C13Gln
SA309475NN-013RFP_vehicle_C13Gln
SA309476NN-015RFP_vehicle_C13Gln
Showing results 1 to 27 of 27
  logo